Olmesartan medoxomil

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Olmesartan medoxomil

Examples of brand names: Olmetec [DE]

ATC code: C09CA08

Main use (for orientation): Hypertension

Documented research summary

Within the documented search scope, no sufficiently attributable cannabinoid pair is established for Olmesartan medoxomil. The structured assessment distinguishes documented drug context from the absence of specific interaction evidence. Missing data do not establish safety.

Uncertainties and limitations

No specific cannabinoid combination study; sartan mechanisms are not all interchangeable. Do not independently change prescribed medicines on the basis of this research dataset.

Structured assessment

Category: Drug context

Cannabinoid scope: No specifically substantiated pair involving a registered cannabinoid in the material assessed; no claim that all 28 cannabinoids were comprehensively reviewed simultaneously.

Evidence status: Drug properties supported by product information; insufficient evidence for a specific cannabinoid–drug pair effect.

Mechanism / drug context: Olmesartan medoxomil is activated to olmesartan by ester hydrolysis; little further metabolism thereafter.

Type of supporting material: Product information and documented individual literature screening; no clinical pair trial approved for use as evidence.

Clinical interpretation: CYP inhibition does not automatically mean inhibition of this prodrug activation.

Context: The medoxomil prodrug and the active drug were assessed separately.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [VD_LABEL_D0222]: Original product information: drug context, not evidence for a cannabinoid–drug pair

Statement supported: Olmesartan medoxomil is activated to olmesartan by ester hydrolysis; little further metabolism thereafter.

Source: OLMESARTAN MEDOXOMIL TABLET [UMEDICA LABORATORIES USA INC.] – DailyMed SPL [VD_LABEL_D0222]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: All individual review fields read. Original product information was rechecked only in the relevant pharmacokinetic/interaction excerpts; no complete recertification of all labels or worldwide full-text search. Literature access was based on the previously documented review; only the listed web sources were additionally read in this round. No specific cannabinoid combination study; sartan mechanisms are not all interchangeable.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[VD_LABEL_D0222] OLMESARTAN MEDOXOMIL TABLET [UMEDICA LABORATORIES USA INC.] – DailyMed SPL

Original source / bibliographic reference

Authors: Marketing authorisation holder / label provider according to the linked DailyMed product information

Year: 2026

Source type: Regulatory product information (US SPL)

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility